Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04991870 · ClinicalTrials.gov registry record · Phase 1
Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
A Phase 1 study of Recurrent Gliosarcoma and Recurrent Supratentorial Glioblastoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04991870 is a Phase 1 study of Recurrent Gliosarcoma and Recurrent Supratentorial Glioblastoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 25 participants, below the 33-participant average among 7 other Recurrent Gliosarcoma trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04991870, a Phase 1 study of Recurrent Gliosarcoma and Recurrent Supratentorial Glioblastoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood \[CB\]-NK-TGF-betaR2-/NR3C1-) in treating patients with glioblastoma that has come back (recurrent). CB-NK-TGF-betaR2-/NR3C1- cells are genetically changed immune cells that may help to control the disease.
Conditions Studied
Interventions
- PROCEDURE Resection
- BIOLOGICAL Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-04-28 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04991870
The ClinicalTrials.gov registry entry for NCT04991870 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 33-participant average among 7 other Recurrent Gliosarcoma trials with a reported enrollment target (24% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Gliosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Resection is the first listed.
NCT04991870 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04991870 about?
NCT04991870 is a clinical study titled "Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM". This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood \[CB\]-NK-TGF-betaR2-/NR3C1-) in treating patients with glioblastoma that has come back (recurrent). CB-NK-TGF-betaR2-/NR...
What is the current status of trial NCT04991870?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2023-04-28. Estimated completion is 2027-01-31.
What conditions does trial NCT04991870 study?
This clinical trial studies the following conditions: Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma, Supratentorial Gliosarcoma.
What interventions are being tested in trial NCT04991870?
The interventions under investigation include: Resection (PROCEDURE), Cord Blood-derived Expanded Allogeneic Natural Killer Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04991870?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04991870 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Gliosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
RECRUITING · Phase 1
-
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
RECRUITING · Phase 1
-
Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide
ACTIVE NOT RECRUITING · Phase 1
-
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
ACTIVE NOT RECRUITING · Phase 1
-
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
ACTIVE NOT RECRUITING · Phase 1
-
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.